British pharma major AstraZeneca (LSE: AZN) has announced positive interim results from the AMPLIFY Phase III trial of Calquence (acalabrutinib).
The study, which tests the BTK blocker in combination with venetoclax, with or without obinutuzumab, showed a significant improvement in progression-free survival compared to standard chemoimmunotherapy.
People in the study were treated in the first-line setting for chronic lymphocytic leukemia (CLL), an incurable form of leukemia which is the most common type in adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze